All In Biotech

Drug Trial Radar · NCT04163562

Oral Immunotherapy for Peanut Allergic Patients

A Multicenter Double-blind, Randomized, Placebocontrolled Phase I/II Study to Determine the Safety, Tolerability, Potential Efficacy and Dose Finding of INP20, an Oral Formulation for Treatment of Immunotherapy in Peanut-allergic Patients

Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 11, 2020

Primary completion

May 2025

Study completion Sep 2025

Sponsor

Lead sponsor
InnoUp Farma S.L.Industry
Sponsor type
Industry
First posted
Nov 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral immunotherapy in peanut-allergic patients. The overall study design consists of two sequential periods of Part A and Part B. Part A is a dose escalation study in patients from 12 to 65 years old with a history of immediate hypersensitive reaction to peanut protein. Six diferent oral-dose of INP20 will be administered to 6 cohorts of patients once daily for 2 weeks. Part B is a 6-month double-blind, placebo-controlled, randomized and parallel groups study. Patients will be randomized in a 1:1:1 ratio into three (3) different treatment groups, including placebo and the two doses of peanut protein selected from Part A. They will recieve INP20 once daily for 6 months.

Conditions

  • Peanut Allergy

Interventions

  • INP20Drug

    Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.

  • PlaceboDrug

    Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate, severity, and relationship to treatment of adverse events (AEs) and serious adverse events (SAEs)Time frame: Week 4 and Week 25
  2. Number of patients experiencing any dose limiting toxicity (DLT)Time frame: Week 2

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain · Recruiting

  • Complejo Hospittalario de Navarra

    Pamplona, Navarre, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.